VCYT Share Price Performance
US$35.72
0.19 (0.53%)
24.8% undervalued intrinsic discount
US$47.50
Fair Value
Price US$35.72
AnalystConsensusTarget US$47.50
AnalystHighTarget US$51.00
AnalystLowTarget US$43.00
Fair ValueUS$47.50
Share Pricen/a
Veracyte, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
VCYT Community Narratives
AN
Fair Value US$47.5 24.8% undervalued intrinsic discount
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$51 30.0% undervalued intrinsic discount
Precision Medicine Growth Will Create New Global Opportunities
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$43 16.9% undervalued intrinsic discount
Restrictive US Policies And Commoditized AI Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Precision Medicine Growth Will Create New Global Opportunities
Key Takeaways Accelerating adoption of core diagnostic tests and global expansion position Veracyte for sustained, above-consensus revenue growth and increased market penetration across oncology segments. Technological advances in sequencing, automation, and data platforms are set to drive substantial margin gains, enable reinvestment, and open new, high-value recurring revenue streams.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$51
30.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
13.86% p.a.
Profit Margin
13%
Future PE
53.35x
Price in 2029
US$62.33
Restrictive US Policies And Commoditized AI Will Erode Margins
Key Takeaways Increased reimbursement hurdles and regulatory scrutiny threaten margins, revenue stability, and geographic expansion due to stagnant pricing and operational constraints. Advancements in AI diagnostics risk eroding Veracyte's product differentiation and premium pricing, exacerbating exposure to competitive pressures and market volatility.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$43
16.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
12.91% p.a.
Profit Margin
12.64%
Future PE
48x
Price in 2029
US$53.19
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Key Takeaways Expanding cancer diagnostics portfolio and clinical evidence are driving greater physician adoption, market penetration, and long-term top-line growth. Operational efficiencies, AI integration, and strategic partnerships are enhancing technology differentiation, profitability, and competitive advantage.Read more
92
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$47.5
24.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.45% p.a.
Profit Margin
17.17%
Future PE
40.62x
Price in 2028
US$57.96
Trending Discussion
Recently Updated Narratives
AN
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Fair Value: US$51 30.0% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Fair Value: US$43 16.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Fair Value: US$47.5 24.8% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Veracyte, Inc. Key Details
About VCYT
- Founded
- 2006
- Employees
- 824
- CEO
- WebsiteView website
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
